NEW YORK (GenomeWeb News) – Myriad Genetics today announced a research collaboration for use of the company's homologous recombination deficiency test to identify tumor types that may serve as targets for BioMarin's investigational drug candidate BMN-673.

Myriad's test detects tumors that may be susceptible to DNA-damaging drugs because they no longer can repair double-stranded DNA breaks.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits sequencing newborns is underway.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.